India's Torrent Pharma Q2 earnings to get an acquisition lift, Nomura says
BUZZ-India's Torrent Pharma Q2 earnings to get an acquisition lift, Nomura says ** Shares of India's Torrent Pharmaceuticals TORP.NS rise as much as 2.1% to 4,649.60 rupees
** Nomura ("neutral", TP:4,670 rupees) expects co to report strong Q2 results on Friday, helped by above-market growth in India, rupee depreciation and early cost savings from its JB Pharma acquisition
** Expects co's India business, excluding JB Pharma, to grow 17% y/y, compared with 12% growth in the broader pharmaceutical market, according to Pharmarack data
** Says cost savings from JB Pharma acquisition are materialising ahead of schedule
** Forecasts EBITDA margin of 34.4% in Q2, an expansion of 158 basis points y/y
** Says Q2 sales, EBITDA and profit to exceed consensus estimates by 2%, 5% and 5%, respectively
** TORP rated "buy" on average by 29 analysts, median PT at 5,457.50 rupees--LSEG compiled data
** YTD stock up 19.2%
(Reporting by Surbhi Misra in Bengaluru)
((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))
Recent news on Torrent Pharmaceuticals
See all newsHSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Brief: Torrent Pharma Q2 Consol Net Profit 5.34 Billion Rupees
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
India's Torrent Pharma Q2 earnings to get an acquisition lift, Nomura says